KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Long-Term Investments (2017 - 2025)

Novartis Ag's Long-Term Investments history spans 6 years, with the latest figure at $119.0 million for Q4 2024.

  • For Q4 2024, Long-Term Investments fell 95.44% year-over-year to $119.0 million; the TTM value through Dec 2024 reached $119.0 million, down 95.44%, while the annual FY2024 figure was $119.0 million, 95.44% down from the prior year.
  • Long-Term Investments for Q4 2024 was $119.0 million at Novartis Ag, down from $2.6 billion in the prior quarter.
  • Across five years, Long-Term Investments topped out at $9.6 billion in Q4 2020 and bottomed at $119.0 million in Q4 2024.
  • The 5-year median for Long-Term Investments is $2.4 billion (2022), against an average of $3.0 billion.
  • The largest annual shift saw Long-Term Investments tumbled 97.87% in 2021 before it surged 1076.1% in 2022.
  • A 5-year view of Long-Term Investments shows it stood at $9.6 billion in 2020, then crashed by 97.87% to $205.0 million in 2021, then soared by 1076.1% to $2.4 billion in 2022, then increased by 8.13% to $2.6 billion in 2023, then tumbled by 95.44% to $119.0 million in 2024.
  • Per Business Quant, the three most recent readings for NVS's Long-Term Investments are $119.0 million (Q4 2024), $2.6 billion (Q4 2023), and $2.4 billion (Q4 2022).